These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8471440)

  • 1. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.
    Kiemeney LA; Witjes JA; Verbeek AL; Heijbroek RP; Debruyne FM
    Br J Cancer; 1993 Apr; 67(4):806-12. PubMed ID: 8471440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group.
    Kiemeney LA; Witjes JA; Heijbroek RP; Koper NP; Verbeek AL; Debruyne FM
    Br J Urol; 1994 Feb; 73(2):164-71. PubMed ID: 8131019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group.
    Mulders PF; Hoekstra WJ; Heybroek RP; Schapers ER; Verbeek AL; Oosterhof GO; Debruyne FM
    Eur J Cancer; 1994; 30A(7):914-7. PubMed ID: 7946582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution and prognosis of bladder papillomatosis managed by endoscopic resection and endovesical BCG therapy : about 24 cases.
    Sallami S; Gammoudi A; Cherni R; Chelly I; Horchani A
    Tunis Med; 2013 Oct; 91(10):573-6. PubMed ID: 24281996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
    Saika T; Tsushima T; Nasu Y; Arata R; Kaku H; Kusaka N; Kumon H
    Jpn J Clin Oncol; 2002 Nov; 32(11):461-5. PubMed ID: 12499418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
    Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
    BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of very large superficial bladder tumours: a 10-year experience.
    Gupta SK; Parr NJ
    Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results.
    Hurle R; Manzetti A; Losa A; Micheli E; Ranieri A; Chinaglia D; Lembo A
    Urol Int; 1998; 61(4):220-6. PubMed ID: 10364753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.